Treatment-Related Changes in Bone Turnover and Fracture Risk Reduction in Clinical Trials of Anti-Resorptive Drugs: A Meta-Regression-Reference-Cited by-同舟云学术

Treatment-Related Changes in Bone Turnover and Fracture Risk Reduction in Clinical Trials of Anti-Resorptive Drugs: A Meta-Regression

Published:2018-01-10 Issue:4 Volume:33 Page:634-642
ISSN:0884-0431
Container-title:Journal of Bone and Mineral Research
language:en
Short-container-title:J Bone Miner Res

Author:

Bauer Douglas C¹,Black Dennis M¹,Bouxsein Mary L²,Lui Li-Yung³,Cauley Jane A⁴,de Papp Anne E⁵,Grauer Andreas⁶,Khosla Sundeep⁷,McCulloch Charles E¹,Eastell Richard⁸,

Affiliation:

1. Departments of Medicine and Epidemiology & Biostatistics; University of California, San Francisco; San Francisco CA USA

2. Center for Advanced Orthopedic Studies; Beth Israel Deaconess Medical Center and Harvard Medical School; Boston MA USA

3. California Pacific Medical Center; San Francisco CA USA

4. Department of Epidemiology; Graduate School of Public Health; University of Pittsburgh; Pittsburgh PA USA

5. Merck & Co., Inc.; Kenilworth NJ USA

6. Amgen Inc.; Thousand Oaks CA USA

7. Mayo Clinic Center for Clinical and Translational Science; Rochester MN USA

8. Academic Unit of Bone Metabolism; University of Sheffield; Sheffield UK

Funder

AgNovos Healthcare

American Society for Bone and Mineral Research

Amgen Inc., Daiichi Sankyo, Inc.

Dairy Research Institute

Eli Lilly and Company

Merck Sharp and Dohme

Subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA

Roche Diagnostics Corporation

Publisher

Wiley

Subject

Orthopedics and Sports Medicine,Endocrinology, Diabetes and Metabolism

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/jbmr.3355/fullpdf

Reference34 articles.

1. Bone turnover markers: understanding their value in clinical trials and clinical practice;Civitelli;Osteoporos Int,2009

2. Bisphosphonates for postmenopausal osteoporosis;Eastell;Bone,2011

3. Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards;Vasikaran;Osteoporos Int,2011

4. Relationship between changes in biochemical markers of bone turnover and BMD to predict vertebral fracture risk;Sarkar;J Bone Miner Res,2004

5. Raloxifene reduces fractures in postmenopausal women with osteoporosis;Reginster;Clin Orthop Relat Res,2006

Cited by 56 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Intermittent dosing of zoledronic acid based on bone turnover marker assessment reduces vertebral and non-vertebral fractures;JBMR Plus;2024-05-31

2. Pre-treatment bone mineral density and the benefit of pharmacologic treatment on fracture risk and BMD change: analysis from the FNIH-ASBMR SABRE project;Journal of Bone and Mineral Research;2024-05-01

3. Surrogate markers in assessment of bisphosphonate effectiveness in osteoporosis treatment (bone mineral density, bone turnover markers);Osteoporosis and Bone Diseases;2024-04-17

4. Influence of age on the efficacy of pharmacologic treatments on fracture risk reduction and increases in BMD: RCT results from the FNIH-ASBMR-SABRE project;Journal of Bone and Mineral Research;2024-03-19

5. Development of the new guidelines on osteoporosis;Die Orthopädie;2023-09-11